THURSDAY, July 7 (HealthDay News) -- Cephalosporin susceptibility among Neisseria gonorrhoeae (N. gonorrhoeae) isolates appears to be declining; however, cephalosporins remain an effective treatment for gonorrhea, according to a report in the July 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
The CDC evaluated trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000 to 2010 with data from the Gonococcal Isolate Surveillance Project.
The data revealed that the percentage of isolates with elevated minimum inhibitory concentrations to cephalosporins increased from 0.2 percent in 2000 to 1.4 percent in 2010 for cefixime, and from 0.1 percent in 2000 to 0.3 percent in 2010 for ceftriaxone. The authors note that cephalosporins remain an effective treatment option for gonococcal infections.
"Health care providers should use ceftriaxone and azithromycin for treatment of gonorrhea, remain vigilant for gonorrhea cephalosporin treatment failures, and report treatment failures to their local or state health departments," the authors write.
Full Text
